We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
(+24%)
Cap. Flow
+$552M
Cap. Flow
% of AUM
5.91%
Top 10 Holdings %
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$50.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$39.4M |
| 3 |
Intel
INTC
|
+$29.2M |
| 4 |
Qualcomm
QCOM
|
+$27.6M |
| 5 |
Danaher
DHR
|
+$26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$49.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$41.6M |
| 3 |
ARQL
Arqule Inc
ARQL
|
+$26.5M |
| 4 |
Arrowhead Research
ARWR
|
+$24.9M |
| 5 |
Merck
MRK
|
+$15.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.73% |
| 2 | Technology | 19.55% |
| 3 | Financials | 10.18% |
| 4 | Consumer Discretionary | 9.32% |
| 5 | Communication Services | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Global Payments
GPN
$23B
| $5.49M | 0.06% |
+30,058
| New | +$5.16M |
|
327
Blackrock
BLK
$165B
| $5.4M | 0.06% |
10,745
+76
| +0.7% | +$36.1K |
|
|
AMTD
328
DELISTED
TD Ameritrade Holding Corp
AMTD
| $5.39M | 0.06% |
108,403
+83,383
| +333% | +$3.61M |
|
|
PVLA
329
Palvella Therapeutics
PVLA
$2.03B
| $5.39M | 0.06% |
18,601
+10,351
| +125% | +$2.87M |
|
|
AYR
330
DELISTED
Aircastle Ltd
AYR
| $5.38M | 0.06% |
+167,946
| New | +$4.85M |
|
|
EPZM
331
DELISTED
Epizyme, Inc
EPZM
| $5.35M | 0.06% |
217,338
+105,838
| +95% | +$1.57M |
|
332
PPG Industries
PPG
$26.4B
| $5.29M | 0.06% |
39,605
+1,821
| +5% | +$231K |
|
|
RDUS
333
DELISTED
Radius Health, Inc.
RDUS
| $5.28M | 0.06% |
262,025
-42,000
| -14% | -$1.02M |
|
334
Royal Bank of Canada
RY
$291B
| $5.25M | 0.06% |
66,272
+5,022
| +8% | +$405K |
|
335
Rigel Pharmaceuticals
RIGL
$692M
| $5.23M | 0.06% |
244,300
-3,500
| -1% | -$72.1K |
|
336
RadNet
RDNT
$4.84B
| $5.2M | 0.06% |
256,370
+128,578
| +101% | +$2.2M |
|
337
Atmos Energy
ATO
$29.7B
| $5.2M | 0.06% |
46,483
+1,661
| +4% | +$182K |
|
338
Cummins
CMI
$91.3B
| $5.19M | 0.06% |
29,009
+6,868
| +31% | +$1.21M |
|
339
Ultragenyx Pharmaceutical
RARE
$2.65B
| $5.19M | 0.06% |
121,500
-19,000
| -14% | -$784K |
|
340
Travelers Companies
TRV
$81.4B
| $5.19M | 0.06% |
37,875
-14,093
| -27% | -$1.92M |
|
|
MYOK
341
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $5.14M | 0.06% |
70,500
+9,500
| +16% | +$576K |
|
342
ICICI Bank
IBN
$107B
| $5.12M | 0.05% |
339,177
+171,589
| +102% | +$2.33M |
|
343
Qorvo
QRVO
$7.92B
| $5.1M | 0.05% |
43,865
-14,935
| -25% | -$1.44M |
|
344
UGI
UGI
$7.91B
| $5.06M | 0.05% |
111,979
+2,823
| +3% | +$129K |
|
345
Advanced Drainage Systems
WMS
$11B
| $5.04M | 0.05% |
129,705
+94,135
| +265% | +$3.48M |
|
346
Masco
MAS
$16.4B
| $5.01M | 0.05% |
104,461
-55,507
| -35% | -$2.52M |
|
|
ETFC
347
DELISTED
E*Trade Financial Corporation
ETFC
| $5M | 0.05% |
110,257
+10,698
| +11% | +$457K |
|
348
KeyCorp
KEY
$24.1B
| $5M | 0.05% |
246,891
+67,556
| +38% | +$1.27M |
|
349
AstraZeneca
AZN
$263B
| $4.99M | 0.05% |
+50,008
| New | +$4.71M |
|
350
Simon Property Group
SPG
$75.1B
| $4.98M | 0.05% |
33,428
-3,502
| -9% | -$525K |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q4 2019 Portfolio in Review
As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.
- Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
- Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
- Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
- Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
- Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
- Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
- Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.
Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.